UsAgainstAlzheimer’s 2021 Virtual Advocacy Summit: Unlocking the Promise of Brain Health

UsAgainstAlzheimer's will bring together policy experts, advocates, and health system leaders to discuss and act on policy solutions that can help make the promise of brain health a reality for all communities. From early detection to health equity and economic justice, UsAgainstAlzheimer's brain health agenda puts patients, families, and communities first.

UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s

UsAgainstAlzheimer’s issued the following statement from George Vradenburg, chairman and co-founder, on the Food and Drug Administration’s decision to approve Biogen’s aducanumab, the first disease-modifying therapy for early-stage Alzheimer’s.

Say Hello to BrainGuide

Our new platform BrainGuide™ was featured on The TODAY Show. It empowers people of all ages and communities to understand and take action on brain health and Alzheimer's disease.

Aducanumab and UsAgainstAlzheimer's

Aducanumab is a proposed treatment for early Alzheimer’s disease that is intended to slow the progression of the disease. UsAgainstAlzheimer’s (UsA2) has urged the U.S. Food and Drug Administration to approve aducanumab.

UsAgainstAlzheimer’s Survey Shows Alzheimer’s Patients Value a New Therapy that Slows Progression of Symptoms

New survey results from UsAgainstAlzheimer’s A-LIST shows that patients want FDA to weigh willingness of people with MCI/mild Alzheimer’s to take a disease-modifying therapy.

Paid Leave Alliance for Dementia Caregivers Applauds American Rescue Plan but Urges Action on Paid Leave Support for Caregivers

The Paid Leave Alliance for Dementia Caregivers commends the Biden-Harris for making support for working families a top priority in its $1.9 trillion COVID-19 economic relief proposal but urges the administration to clarify how the proposal's paid leave expansions will cover Americans who care for older adults.

UsAgainstAlzheimer’s 2021 Virtual Advocacy Summit: Unlocking the Promise of Brain Health

UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s

Say Hello to BrainGuide

Aducanumab and UsAgainstAlzheimer's

UsAgainstAlzheimer’s Survey Shows Alzheimer’s Patients Value a New Therapy that Slows Progression of Symptoms

Paid Leave Alliance for Dementia Caregivers Applauds American Rescue Plan but Urges Action on Paid Leave Support for Caregivers

UsAgainstAlzheimer's: Working to End Alzheimer's Disease  

The Alzheimer’s pandemic is the health and social economic crisis of this generation. It is a national and global emergency that has a devastating health, social and economic toll on millions of people living with this disease, their families and caregivers.

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. Since our founding in 2010, we have taken on the toughest problems in the fight to end Alzheimer’s. Our work is driven by the urgency to find effective treatments and the prevention steps needed to reach the time where no one is lost to Alzheimer’s.

We bring all of “Us” together to:

In the past decade, progress has been made, with more hope on the horizon now than ever before.

But every day of delay is another day lost to the millions of people affected by this devastating disease. If nothing changes, by 2050, 14 million Americans will be living with Alzheimer’s at an annual cost of more than $1 trillion. The time to act is now.

Recent News and Blog Posts

  • June 21, 2021

    New Alzheimer’s Treatment Must Be Affordable and Accessible; with Faster and More Inclusive Phase 4 Confirmatory Trial

    The FDA’s approval of Aduhelm is a breakthrough in the fight to...

    Read more
  • UsAgainstAlzheimer's

    UsA2 Research Highlights Burdens on Alzheimer’s Caregivers of Color

    New research from UsAgainstAlzheimer’s shines a light on the challenges faced by...

    Read more
  • June 07, 2021

    UsAgainstAlzheimer’s Hails FDA Approval of Aducanumab, the First Disease-Modifying Therapy for Early-Stage Alzheimer’s

    "This first disease-slowing drug is a dramatic turning point in the fight...

    Read more
  • May 19, 2021

    UsAgainstAlzheimer’s Welcomes Bipartisan Introduction of CHANGE Act to Encourage Early Detection and Diagnosis of Alzheimer’s

    UsAgainstAlzheimer’s welcomed the bipartisan introduction today in Congress of the CHANGE Act...

    Read more
  • May 19, 2021

    Broad Range of Health, Aging, Consumer and Dementia Groups call for Congress to Triple Funding for CDC’s Alzheimer’s Disease and Healthy Aging Program

    More than 50 health, medical, aging, consumer, Alzheimer’s and dementia advocacy groups...

    Read more
  • Nora Super and Cara Levy

    Paid Family Leave Can Build Health and Economic Equity

    The US is woefully unprepared to care for the growing population of...
    Read more

Reports

  • Resources
    Thumbnail

    A-LIST Pulse of the Community: Volume 7, December 2020

    The UsAgainstAlzheimer’s A-LIST® is an online community of more than 8,000 people living with Alzheimer’s and other dementias, current and former caregivers, and those concerned about brain health, who have...

  • Resources
    Thumbnail

    Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

    The effects of where people live, and the social determinants of health are under-recognized and under-appreciated in our national response to effectively treat and prevent Alzheimer’s. This report found that...

  • Resources
    Thumbnail

    2019 Annual Report

    In these pages, you will find highlights of the game-changing accomplishments and tremendous progress of UsAgainstAlzheimer's and our partners in the year of 2019.